MindWalk Holdings (HYFT) Income from Continuing Operations (2020 - 2026)
MindWalk Holdings (HYFT) posted quarterly Income from Continuing Operations of 3096.02 for Q2 2026, up 75.96% year-over-year from 1759.5 in Q2 2025, and up 82.14% quarter-over-quarter from 17339.07 in Q1 2026.
MindWalk Holdings (HYFT) Income from Continuing Operations (2020 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Income from Continuing Operations for 7 consecutive years, with 3096.02 the latest figure, recorded in Q2 2026.
- In Q2 2026, Income from Continuing Operations rose 75.96% year-over-year to 3096.02; the TTM figure through Apr 2026 stood at 2038592965.24 (down 1.47% YoY), while the FY2026 annual figure was 11016999.96, up 53.7% from the prior year.
- Income from Continuing Operations grew to 3096.02 in Q2 2026 per HYFT's latest filing, from 17339.07 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 3124929072.21 in Q3 2023 and bottomed at 32906903.72 in Q2 2023.
- Historically, Income from Continuing Operations has averaged 470264355.73 across 5 years, with a median of 995956.02 in 2023.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations plunged 328.73% — and 2023, when it jumped 1025793.57%.
- MindWalk Holdings' Income from Continuing Operations stood at 3934631.5 in 2022, then jumped by 32982.56% to 1301676711.67 in 2023, then sank by 99.91% to 1209740.94 in 2024, then surged by 87.65% to 2270047.98 in 2025, then sank by 100.14% to 3096.02 in 2026.
- Business Quant data shows HYFT's Income from Continuing Operations at 3096.02 in Q2 2026, 17339.07 in Q1 2026, and 2270047.98 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -290.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -3,096.02 |
| Jan 31, 2026 | -17,339.07 |
| Oct 31, 2025 | 2.27 Mn |
| Jul 31, 2025 | 2.04 Bn |
| Apr 30, 2025 | -12,878.91 |
| Jan 31, 2025 | 12.71 Mn |
| Oct 31, 2024 | 1.21 Mn |
| Jul 31, 2024 | 2.06 Bn |
| Apr 30, 2024 | -27.69 Mn |
| Jan 31, 2024 | 1.70 Mn |
| Oct 31, 2023 | 1.30 Bn |
| Jul 31, 2023 | 3.12 Bn |
| Apr 30, 2023 | -32.91 Mn |
| Jan 31, 2023 | 782,171.11 |
| Oct 31, 2022 | 3.93 Mn |
| Jul 31, 2022 | 304,605.58 |
| Apr 30, 2022 | -15.40 Mn |
| Jan 31, 2022 | -167,410.40 |
| Oct 31, 2021 | -4,326.39 |
| Jul 31, 2021 | -2,568.93 |